Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Protocols / Development of a magneto-nanosensor (MNS) array for prostate cancer biomarkers

Development of a magneto-nanosensor (MNS) array for prostate cancer biomarkers

Gambhir, SanjivStanford University

No coordinating investigator defined.

No involved investigator sites defined.

G.I. and Other Associated Cancers Research Group

Our goal is to develop a blood-based biomarker magneto-nanosensor array for the accurate early detection and prognostication of prostate cancer

Specific Aim 1: To adapt the magneto-nanosensor array platform to the multiplex measurement of prostate cancer biomarkers for detection and progression. To accomplish this we will functionalize our magneto-nanosensor with capture antibodies for an extended panel of leading biomarker candidates for prostate cancer detection and prognostication rigorously selected from the literature. Initial experiments will be performed to evaluate the performance of the array to detect spiked samples with known quantities of biomarkers, to establish calibration curves, determine the lower limits of detection, and assess reproducibility. Once the array has been completed we will progress to evaluate it using the clinical discovery sample set described in Aim #2. Specific Aim 2: To evaluate the accuracy of the prostate cancer magneto-nanosensor array to classify clinical cancer and control specimens from the Stanford serum bank. For this aim we will test the ability of the array to accurately classify archival serum samples drawn from prostate cancer patients before and after radical prostatectomy, and from patients with positive and negative biopsies. These sera were collected by the PSA analysis laboratory in the Urology Department at the Stanford University Medical Center.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.